Cargando…

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

As new vaccine technologies and platforms, such as nanoparticles and novel adjuvants, are developed to aid in the establishment of a universal influenza vaccine, studying traditional influenza split/subunit vaccines should not be overlooked. Commercially available vaccines are typically studied in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Myers, Mallory L., Gallagher, John R., Woolfork, De’Marcus D., Stradtmann-Carvalho, Regan K., Maldonado-Puga, Samantha, Bock, Kevin W., Boyoglu-Barnum, Seyhan, Syeda, Hubza, Creanga, Adrian, Alves, Derron A., Kanekiyo, Masaru, Harris, Audray K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561127/ https://www.ncbi.nlm.nih.gov/pubmed/36248851 http://dx.doi.org/10.3389/fimmu.2022.1002286

Ejemplares similares

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2023)

Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes
por: McCraw, Dustin M., et al.
Publicado: (2023)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines?
por: Paget, John, et al.
Publicado: (2022)

Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2019)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2018)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
por: Bianculli, Pablo Manuel, et al.
Publicado: (2022)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
por: You, Joyce HS, et al.
Publicado: (2014)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study
por: Milne, George J., et al.
Publicado: (2016)

From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
por: Crépey, Pascal, et al.
Publicado: (2020)

Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance
por: Skowronski, Danuta M., et al.
Publicado: (2012)

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
por: Dolk, Christiaan, et al.
Publicado: (2016)

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
por: Kim, Yun-Kyung, et al.
Publicado: (2018)

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2019)

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017
por: Gaglani, Manjusha, et al.
Publicado: (2020)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
por: Arbo, Antonio, et al.
Publicado: (2022)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

1954. A Randomized Study to Evaluate the Shedding and Immunogenicity of H1N1 Strains in Trivalent and Quadrivalent Formulations of FluMist in Children 24 to <48 Months of Age
por: Mallory, Raburn, et al.
Publicado: (2018)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

989. Clinical Effectiveness of High-Dose Trivalent vs. Quadrivalent Influenza Vaccination Among Veterans Health Administration Patients
por: Young-Xu, Yinong, et al.
Publicado: (2018)

Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach
por: Brogan, Anita J., et al.
Publicado: (2016)

Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil – comparison of outcomes from different static model types
por: Van Bellinghen, Laure-Anne, et al.
Publicado: (2018)

Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season
por: Serradell, Laurence, et al.
Publicado: (2020)

Surveillance on the Immune Effectiveness of Quadrivalent andTrivalent Split Influenza Vaccines — Shenzhen Cityand Changzhou City, China, 2018–2019
por: Shu, Liumei, et al.
Publicado: (2020)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Trivalent Combination Vaccine Induces Broad Heterologous Immune Responses to Norovirus and Rotavirus in Mice
por: Tamminen, Kirsi, et al.
Publicado: (2013)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6–35 Months
por: Lee, Jee Hyun, et al.
Publicado: (2019)

Transmission Network of Measles During the Yamagata Outbreak in Japan, 2017
por: Kobayashi, Tetsuro, et al.
Publicado: (2022)

Ten-year longitudinal investigation of astigmatism: The Yamagata Study (Funagata)
por: Namba, Hiroyuki, et al.
Publicado: (2022)

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
por: Kanekiyo, Masaru, et al.
Publicado: (2019)

Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens
por: Mysore, Vijayashree, et al.
Publicado: (2021)

Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020
por: Morikane, Keita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n81lladgalihdl6tc33718on6m